Showing 5831-5840 of 8080 results for "".
- Dr. James Del Rosso Presents 'Medicine Chest' at Fall Clinicalhttps://practicaldermatology.com/news/dr-james-del-rossos-presents-medicine-chest-at-fall-clinical/2484096/A curated overview of skincare fundamentals, treatment pearls, and emerging data across acne, rosacea, hyperpigmentation, hidradenitis suppurativa (HS), and more was on display as James Q. Del Rosso, DO, presented “What’s New in the Medicine Chest” at the 2025 Fall Clinical Dermatology Conference
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- New Deuruxolitinib Data Show It Meets 'The Need for Speed'https://practicaldermatology.com/news/new-deuruxolitinib-data-show-it-meets-the-need-for-speed/2484089/Deuruxolitinib resulted in significant hair regrowth starting at Week 8, continually improving through Week 24, and the 8-mg and 12-mg BID doses showed significant efficacy vs placebo across subgroups, according to new data presented at the 2025 Fall Clinical Dermatology Conference. Other
- Arcutis Presents New ZORYVE Data in AD at Fall Clinical 2025https://practicaldermatology.com/news/arcutis-presents-new-zoryve-data-in-ad-at-fall-clinical-2025/2484062/Updates and new data sets from the INTEGUMENT trial program, including new quality-of-life and efficacy data for ZORYVE® (roflumilast) cream in pediatric and adult patients with atopic dermatitis (AD), were featured at the 2025 Fall Clinical Dermatology Conference
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,
- IL-17A Inhibitors Linked with Scalp and Gut Microbiota Improvement in Psoriasis Patientshttps://practicaldermatology.com/news/il-17a-inhibitors-linked-with-scalp-and-gut-microbiota-improvement-in-psoriasis-patients/2484034/Treatment with IL-17A inhibitors may help rebalance disrupted scalp and gut microbiota in patients with moderate-to-severe psoriasis vulgaris, according to a new study. Researchers collected scalp and fecal samples from 15 adu
- Lower Neighborhood SES Linked to Increased HS Severity at Diagnosis: Analysishttps://practicaldermatology.com/news/lower-neighborhood-ses-linked-to-increased-hidradenitis-suppurativa-severity-at-diagnosis/2483997/New research suggests that lower neighborhood socioeconomic status (nSES) was associated with more severe hidradenitis suppurativa (HS) at the time of diagnosis. The recent cross-sectional analysis of 462 patients newly diagno
- Study Links Structural and Immune Risk Factors to Skin Conditions in PWHhttps://practicaldermatology.com/news/study-links-structural-and-immune-risk-factors-to-skin-conditions-in-pwh/2483949/Nearly half of people living with HIV (PWH) are diagnosed with at least one dermatologic condition despite advances in antiretroviral therapy (ART), according to a longitudinal cohort study published through the DC Cohort. Accor
- Dr. Michelle Henry Highlights Noninvasive Periorbital Rejuvenationhttps://practicaldermatology.com/news/dr-michelle-henry-highlights-noninvasive-periorbital-rejuvenation/2483904/Understanding facial aging patterns specific to richly pigmented skin and adjusting treatment approaches accordingly, especially as patient preferences shift away from traditional lower eyelid filler, is key in managing periorbital aging in patients with skin of color, Michelle Henry, MD, FAAD, s